menu
    • menu
    [{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Methamphetamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University Hospital Basel","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Launches Empath Bio to Treat Post-Traumatic Stress Disorder with Novel Mdma Product","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medic.."}]

    Find Clinical Drug Pipeline Developments & Deals for Desoxyn

    Menu

    Desoxyn

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mind Medicine

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed

                            Mind Medicine

                            U.S.A arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methamphetamine Hydrochloride,LSD

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD

                            Details : The MDMA-LSD trial, the first-ever to combine both drugs, is scheduled to start in the fourth quarter in Basel, Switzerland. Combined MDMA-LSD treatments have the potential to create next-generation psych...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 25, 2020

                            Lead Product(s) : Methamphetamine Hydrochloride,LSD

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATAI Life Sciences

                            Germany arrow
                            26th North American ISSX
                            Not Confirmed

                            ATAI Life Sciences

                            Germany arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methamphetamine Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atai Life Sciences Launches Empath Bio to Treat Post-Traumatic Stress Disorder with Novel Mdma Pro...

                            Details : EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indi...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : Methamphetamine Hydrochloride

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Hospital Basel

                            Country arrow
                            26th North American ISSX
                            Not Confirmed

                            University Hospital Basel

                            Country arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methamphetamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Partner/Sponsor/Collaborator : Mind Medicine

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

                            Details : MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a compo...

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2020

                            Lead Product(s) : Methamphetamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Partner/Sponsor/Collaborator : Mind Medicine

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth